Lung Cancer Clinical Trials in Houston

Showing 341-360 of 620 trials

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more

Klus Pharma Inc.49 participantsStarted Jul 2018

Sarasota, Florida, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +7 more locations

COMPLETEDPhase 1/2< 1 mile

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817

The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Ovarian CancerCervical CancerEndometrial Cancer+5 more

Genmab306 participantsStarted Nov 2016

Phoenix, Arizona, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +38 more locations

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Lung Cancer Trials in Other Cities

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Other Conditions in Houston